Trial Profile
Micardis/MicardisPlus PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms PROTEKT
- Sponsors Boehringer Ingelheim
- 17 Oct 2014 New trial record